Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)

Overview of attention for article published in British Medical Journal, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 7 news outlets
blogs: 3 blogs
twitter: 303 X users
facebook: 4 Facebook pages
wikipedia: 1 Wikipedia page

googleplus: 3 Google+ users
reddit: 2 Redditors
video: 1 YouTube creator
guideline: 1 clinical guideline source

Readers on

mendeley: 208 Mendeley

So far, Altmetric has seen 5 public wall posts from 4 users.

Perfection Towards Medication Care, 30 Jan 2019

Many patients with unipolar major depression who are resistant to initial treatment with antidepressant monotherapy receive…

Virginia Tech Carilion School of Medicine Library, 28 Nov 2018

New study published in BMJ called "Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care…

BMJ, 04 Nov 2018

Patients who took mirtazapine in addition to an SSRI or SNRI for depression were more likely to experience adverse effects and…

Enfermeria y Seguridad del Paciente, 03 Nov 2018

https://www.bmj.com/content/363/bmj.k4218?utm_source=etoc

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 1 additional Facebook posts.